A recent survey of 588 Canadian patients revealed that many patients had serious concerns about biosimilar substitution.
A recent survey of 588 Canadian patients revealed that many patients had serious concerns about biosimilar substitution.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.